GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over
MWN-AI** Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology firm focused on developing vaccines and immunotherapies, has endorsed a critical call to action regarding the ongoing mpox epidemic. In a recent article published in PLOS Medicine, Dr. Rosamund Lewis, Head of the WHO's Poxviruses Programme, stresses that the mpox epidemic is not over and demands sustained efforts to reduce its disproportionate impact in Africa and the persistent global risk associated with the disease.
The article highlights ongoing mpox transmission, morbidity, and mortality, particularly in vulnerable populations. GeoVax's CEO, David Dodd, pointed out the urgent need for continued political support, financial investment, and vaccine availability to combat the disease effectively. He emphasized that complacency could have dire consequences, as mpox continues to evolve and spread.
In response to these challenges, GeoVax is advancing its GEO-MVA vaccine, a Modified Vaccinia Ankara-based solution aimed at addressing the global reliance on a single MVA vaccine supplier. The company has completed clinical material for GEO-MVA and is preparing for a pivotal Phase 3 immunobridging study, expected to begin in late 2026, with results anticipated in mid-2027. This development aligns with guidance from the European Medicines Agency for an expedited regulatory pathway.
GeoVax is committed to creating a resilient and diversified vaccine supply chain, recognizing that a strong, ongoing response is crucial as the global health landscape evolves. The company aims to enhance MVA vaccine capacity, helping ensure long-term preparedness against mpox and similar infectious threats. By supporting this initiative, GeoVax reinforces its dedication to global health and public safety, advocating for strategic investments and manufacturing diversification.
MWN-AI** Analysis
**Market Analysis and Advice for GeoVax Labs, Inc. (Nasdaq: GOVX)**
As GeoVax Labs, Inc. (GOVX) positions itself within the evolving landscape of infectious disease response, particularly regarding mpox (previously known as monkeypox), the company's endorsement of sustained global action underscores a significant strategic pivot in public health priorities. Recent commentary emphasizes that the mpox epidemic still poses substantial threats, especially in under-resourced areas, setting the stage for the potential uptick in demand for effective vaccines.
GeoVax's GEO-MVA vaccine, designed to enhance the global modified vaccinia Ankara (MVA) supply, demonstrates a robust response to the urgent needs articulated by health authorities. The planned initiation of a pivotal Phase 3 clinical study in late 2026 and associated expedited registration pathway bolster investor confidence in the company's prospects. With anticipated results available by mid-2027, GeoVax is well-poised to not only secure regulatory approvals but also to tap into procurement discussions crucial for its growth.
Investors should watch for developments surrounding the completion of clinical materials and the initiation of the Phase 3 study, as these milestones can drive share price appreciation. The current global discourse around vaccine supply diversification and GeoVax’s commitment to expand MVA manufacturing capacity offers a favorable outlook in a market where health preparedness is increasingly prioritized.
However, potential investors should remain cautious of inherent risks associated with clinical trial outcomes, competitive market dynamics, and the company's ability to scale production. Given these variables, a diversified investment approach could mitigate potential volatility. Moreover, stakeholders should monitor regulatory developments closely, as these could significantly impact share performance. Overall, GeoVax Labs presents a compelling opportunity within a critical public health narrative, contingent on continued execution against its clinical and manufacturing milestones.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company Highlights GEO-MVA Manufacturing Readiness and Clear Clinical Pathway to Support Global Supply Diversification
ATLANTA - February 17, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today issued a statement endorsing the urgent call to action articulated by Rosamund Lewis, MD (WHO Head, Poxviruses Programme) and colleagues in their recently published PLOS Medicine article, “The mpox epidemic is not over: Reducing disproportionate burden in Africa and persistent global risk require a sustained response.” (https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004893&type=printable)
The article underscores that, despite declining attention in some regions, mpox transmission, morbidity, and mortality continue, particularly across Africa, driven by evolving viral clades, constrained vaccine supply, and persistent inequities in access to countermeasures. Dr. Lewis reinforced these concerns in a recent public call to action, emphasizing that sustained political will, financing, and expanded vaccine availability remain essential to controlling mpox as a global health threat.
“GeoVax strongly endorses Dr. Lewis’s message that the mpox epidemic is not over and that complacency would be a costly mistake,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “The data are clear: mpox continues to circulate, evolve, and disproportionately impact vulnerable populations. A durable response requires sustained investment, diversified vaccine supply, and readiness that extends beyond reactive surge manufacturing.”
GEO-MVA: Advancing Toward an Expanded Global MVA Vaccine Supply
GeoVax’s GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for the prevention of mpox and smallpox, is being developed specifically to help address the structural vulnerabilities highlighted in the PLOS Medicine analysis - most notably the world’s continued dependence on a single manufacturer for licensed MVA vaccine supply.
Key GEO-MVA program milestones include:
- Completion of GEO-MVA clinical material, positioning the program for late-stage clinical execution and supply readiness
- Planned initiation of a pivotal Phase 3 immunobridging study in Q4 2026, aligned with formal Scientific Advice from the European Medicines Agency supporting an expedited registration pathway
- Anticipated availability of immunobridging results in Q2 2027, supporting potential regulatory submissions and procurement discussions
“With a clearly defined regulatory pathway ahead, GEO-MVA is transitioning from preparedness planning to execution,” Dodd added. “This program is designed not only to meet regulatory requirements, but to support long-term global readiness by expanding MVA vaccine capacity in a market that remains chronically supply-constrained.”
Sustained Preparedness Requires Sustained Supply
The PLOS Medicine authors emphasize that mpox will continue to pose a global risk due to ongoing zoonotic spillover, viral evolution, and efficient transmission networks, particularly in settings where health systems are under-resourced. GeoVax believes these realities reinforce the need for redundant, geographically diversified MVA manufacturing capacity - a principle that underpins the GEO-MVA program.
“As the mpox response evolves from emergency reaction to long-term control, vaccine supply resilience becomes a cornerstone of preparedness,” said Dodd. “GeoVax is committed to supporting that objective by advancing GEO-MVA as an additional MVA vaccine option for public-health and biodefense stakeholders worldwide.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
View the original release on www.newmediawire.com
FAQ**
How does GeoVax Labs Inc. (GOVX) plan to ensure the expansion of MVA vaccine supply and mitigate reliance on a single manufacturer as discussed in the recent PLOS Medicine article?
What specific milestones does GeoVax Labs Inc. (GOVX) aim to achieve before the anticipated initiation of the pivotal Phase 3 immunobridging study for the GEO-MVA vaccine in Q4 2026?
In what ways does GeoVax Labs Inc. (GOVX) intend to address the disparities in access to mpox vaccines, especially in under-resourced health systems highlighted by the WHO and PLOS Medicine?
How does the GEO-MVA program align with GeoVax Labs Inc. (GOVX)'s overall strategy to diversify vaccine manufacturing capacity and enhance global preparedness against infectious diseases?
**MWN-AI FAQ is based on asking OpenAI questions about GeoVax Labs Inc. (NASDAQ: GOVX).
NASDAQ: GOVX
GOVX Trading
6.7% G/L:
$1.99 Last:
21,883 Volume:
$1.97 Open:
